Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Neupogen (filgrastim) Market Growth From $ Billion In 2026 To $ Billion By 2030 At A CAGR Of %
The market for neupogen (filgrastim) has exhibited robust expansion in recent times. Its value is projected to rise from $1.4 million in 2025 to $1.48 million in 2026, reflecting a compound annual growth rate (CAGR) of 5.5%. This historic growth has been driven by factors such as increased chemotherapy usage, a heightened infection risk among neutropenic patients, clinically proven benefits of G-CSF therapy, cancer care concentrated in hospitals, and a scarcity of early-stage treatment alternatives.
Over the coming years, the neupogen (filgrastim) market is projected to experience robust expansion. By 2030, its value is anticipated to reach $1.81 million, reflecting a compound annual growth rate (CAGR) of 5.2%. This upward trajectory during the forecast period can be attributed to several factors: the rising prevalence of cancer, wider acceptance of biosimilars, growth in outpatient oncology services, improved patient access to biologic therapies, and a heightened emphasis on preventing infections. Key developments shaping this forecast include the growing integration of supportive care in oncology, better management of chemotherapy-induced neutropenia, broader utilization of biologic growth factors, a transition toward outpatient settings for neutropenia treatment, and an increasing reliance on biosimilar alternatives.
Download A Free Sample Report For Comprehensive Market Insights:
#Neupogen (filgrastim) Market Growth Factors: Which Forces Are Supporting Market Expansion?
The expected rise in the frequency of diverse health conditions is anticipated to accelerate the expansion of the neupogen (filgrastim) market moving forward. Health conditions refer to irregularities in the body’s structure or function that generate distinct symptoms or impact particular sites, frequently stemming from infections, genetic factors, environmental influences, or lifestyle decisions. The growing occurrence of various health conditions is fueled by elements like aging populations, inactive lifestyles, increasing environmental contamination, unhealthy eating patterns, and the worldwide dispersion of infectious agents. Neupogen (filgrastim) mitigates the complications arising from chemotherapy-induced neutropenia by boosting neutrophil production, thereby strengthening the immune system’s capacity to fight infections in patients with compromised immunity. It plays a key role in lowering hospital admission rates, minimizing infection hazards, and facilitating uninterrupted cancer treatment schedules for individuals undergoing intensive therapies. For example, in April 2024, Allergy UK, a national charity based in the United Kingdom, reported that over 21 million individuals in the UK suffer from allergies, making it the most frequently cited chronic health issue in 2022, and forecasts suggest that by 2026, half of Europe’s population will have at least one allergy. Moreover, in June 2022, data released by Macmillan Cancer Support, a UK-based cancer charity, indicated that the number of people living with cancer reached 3 million in 2022, with projections showing an increase to nearly 3.5 million by 2025 and 4 million by 2030 within the UK. Consequently, the rising prevalence of various diseases is fueling the growth of the neupogen (filgrastim) market.
Government-led healthcare research and development efforts are set to drive the advancement of the neupogen (filgrastim) market in the future. Such government-led efforts encompass specific actions, programs, policies, or projects carried out by authorities at different tiers (local, regional, national, or global) to tackle particular challenges, realize certain objectives, or foster beneficial societal changes. Numerous government bodies are launching healthcare initiatives to support various aspects, including neupogen (filgrastim). As an example, in May 2023, the Department of Health and Social Care, a UK government authority, unveiled a $749.09 million (£650 million) “Life Sci for Growth” package aimed at boosting the life sciences industry. This package allocates $139.44 million (£121 million) to expedite commercial clinical trials, $177.47 million (£154 million) to enhance the UK Biobank’s capacities, and incentives up to $288.11 million (£250 million) to attract pension-fund investments into the sector. Hence, government initiatives for healthcare research and development are propelling the neupogen (filgrastim) market.
Neupogen (filgrastim) Market Segment Landscape: Which Areas Lead Market Development?
The neupogen (filgrastim) market covered in this report is segmented –
1) By Drug Type: Biologic, Biosimilar
2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Neupogen (filgrastim) Market Industry Trends: What Changes Are Reshaping Demand?
Key players in the neupogen (filgrastim) market are placing a strong emphasis on creating novel products like filgrastim biosimilars, aiming to deliver cost-effective and accessible treatment options for chemotherapy-induced neutropenia. These filgrastim biosimilars are biologic agents designed to closely match the original filgrastim (Neupogen) in terms of safety, efficacy, and structural composition, and they are primarily utilized to boost neutrophil production in patients undergoing chemotherapy, thereby preventing neutropenia. A notable example occurred in September 2024 when Tanvex BioPharma, a biopharmaceutical firm based in the United States, secured approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid), a biosimilar that references Amgen’s Neupogen. This product was among three biosimilars authorized by the FDA on that same date, adding to a total of 55 biosimilars that have been approved in the United States as of June 2024. Nypozi is indicated for reducing the occurrence of infection, particularly febrile neutropenia, in patients with non-myeloid malignancies who are being treated with myelosuppressive anticancer drugs.
Neupogen (filgrastim) Market Industry Leaders And Market Competition
Major companies operating in the neupogen (filgrastim) market are Amgen Inc.
Access The Complete Neupogen (filgrastim) Market Report:
Neupogen (filgrastim) Market Largest Region By Revenue And Market Share
North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neupogen (filgrastim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model